SARASOTA, Fla.--(BUSINESS WIRE)--Vycellix, Inc., a privately-held biotechnology company advancing novel products capable of optimizing human immune response against disease with a focus on cancers, today announced that its CEO, Evren Alici, M.D., Ph.D., will present at the Innate Killer Summit 2016 to be held in San Diego, CA, May 16-18. The Company expects to initially advance its technology for the treatment of hematological malignancies and sarcomas.
Dr. Alici will present two sessions at the Summit including a talk titled, “Screening for the Best Response for Adoptively Transferred NK-cells” and a half-day workshop titled, “Cell Expansion Methodologies for Enhanced Efficacy”. Dr. Alici serves as the Head of the Gene & Cell Therapy Group, Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden and as Visiting Research Professor at the NSU Cell Therapy Institute, Ft. Lauderdale, Florida.
Vycellix’s pre-IND product pipeline includes the novel molecules VY-OZ and VY-X which have demonstrated unrivaled enhancement of T-cells and natural killer cells (NK-cells). These products have shown to be capable of: delivering optimal and cost-effective gene modification; rapidly increasing in vivo and ex vivo immune response, and; yielding unprecedented amplification of killing capacity for cytotoxic lymphocytes.
To schedule a meeting with Vycellix at the Innate Killer Summit in San Diego, May 16-18, or at the ASCO Annual Meeting, June 3-7 in Chicago, please contact Douglas Calder, President, at dcalder@vycellix.com.
About Vycellix, Inc.:
Vycellix is advancing its proprietary pipeline of novel immunomodulators as therapeutics for cancers and infectious disease, as well as establishing these products as platform technology for the efficient, cost-effective modulation of cell and gene therapies. For more information, please visit: www.Vycellix.com.
